Novartis Announces Positive Biomarker Results for Del-brax in FSHD
The FSHD community received encouraging news today as Novartis announced that delpacibart braxlosiran (del-brax) met the primary and key secondary endpoints in the biomarker cohort of the Phase 1/2 FORTITUDE […]